
|Articles|March 5, 2015
Clonal Heterogeneity in Urothelial Cancer
Author(s)Bishoy Faltas, MD
Bishoy Faltas, MD, clinical fellow, Weill Cornell Medical College, discusses clonal heterogeneity in platinum-resistant metastatic urothelial cancer.
Advertisement
Clinical Pearls
Bishoy Faltas, MD, clinical fellow, Weill Cornell Medical College, discussesclonal heterogeneity in platinum-resistant metastatic urothelial cancer.
- This study found a significant degree of both inter- and intra-patient heterogeneity.
- There were differences in the patterns of evolution of molecular alterations in these samples.
- Subclonal mutations went on to be enriched in and constitute most mutations in metastatic samples.
- Mutations in primary samples were identified that were not enriched in metastatic samples.
- It was found that the metastatic samples continued to change even after evolving from the primary tumor samples.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC
2
Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer
3
FDA Approval Sought for Selinexor Plus Ruxolitinib in Myelofibrosis
4
Zanidatamab/Chemo Achieves OS Benefit in HER2+ Gastroesopheageal Cancer
5





























